Mitochondrial dysfunction in amyotrophic lateral sclerosis - a valid pharmacological target?

Area of Science:

• Neuroscience
• Cell Biology
• Genetics

Background:

• Amyotrophic lateral sclerosis (ALS) is a fatal adult-onset neurodegenerative disease.
• ALS involves the progressive death of motor neurons, leading to paralysis.
• Mitochondrial dysfunction, including changes in morphology, energy production, and calcium balance, is a key pathological feature in ALS.

Purpose of the Study:

• To review recent advancements in understanding the role of mitochondrial biology in ALS pathogenesis.
• To explore the therapeutic potential of targeting mitochondrial pathways for ALS treatment.

Main Methods:

• Literature review of recent research on mitochondrial biology and ALS.
• Analysis of studies investigating mitochondrial function in ALS models and patients.

Main Results:

• Impaired mitochondrial function is strongly implicated in the rapid neurodegeneration observed in ALS.
• Specific alterations in mitochondrial morphology, bioenergetics, and calcium homeostasis are consistently reported in ALS.
• Pharmacological interventions targeting mitochondrial pathways show potential in preclinical studies.

Conclusions:

• Mitochondrial dysfunction is a pivotal factor in ALS pathogenesis.
• Targeting mitochondrial biology represents a promising therapeutic avenue for slowing ALS progression.